Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)

In a clinical study of 264 PH-LHD patients, treatment outcomes showed a 51% reduction in the risk of clinical worsening and a 35.5% decrease in recurrent clinical events. Functional capacity improvements were sustained alongside these event reductions, supporting multi-dimensional therapeutic benefits. Overall, the results are materially positive for efficacy signals, though the snippet does not indicate regulatory or commercial milestones.